Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Frequency Therapeutics	RedHill Biopharma	Hookipa Pharma	Orphazyme A/S	Ampio Pharmaceuticals
Symbol	NASDAQ:FREQ	NASDAQ:RDHL	NASDAQ:HOOK	NASDAQ:ORPH	NYSEAMERICAN:AMPE
Price Information
Current Price	$8.66	$6.22	$17.56	$5.51	$1.77
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.5	1.4	1.0	1.0	1.3
Analysis Score	3.5	3.5	2.5	3.0	3.5
Community Score	2.7	2.9	2.6	2.1	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	0.0	0.0	0.0
Earnings & Valuation Score	0.6	0.6	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$37.00	$20.00	$21.86	$16.00	$4.00
% Upside from Price Target	327.25% upside	221.54% upside	24.47% upside	190.38% upside	125.99% upside
Trade Information
Market Cap	$296.34 million	$288.58 million	$456.47 million	$192.59 million	$346.37 million
Beta	0.69	1.71	1.18	N/A	1.79
Average Volume	1,130,866	476,988	183,602	41,807	3,047,174
Sales & Book Value
Annual Revenue	$28.95 million	$6.29 million	$11.94 million	N/A	N/A
Price / Sales	10.24	45.88	38.23	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$5.44 per share	$2.74 per share	$5.46 per share	N/A	$0.04 per share
Price / Book	1.59	2.27	3.22	N/A	N/A
Profitability
Net Income	$-18,750,000.00	$-42,300,000.00	$-43,040,000.00	N/A	$-13,630,000.00
EPS	($2.29)	($1.40)	($2.41)	N/A	($0.14)
Trailing P/E Ratio	N/A	N/A	N/A	0.00	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-68.59%	-142.81%	-232.00%	N/A	N/A
Return on Equity (ROE)	-12.56%	-152.19%	-39.58%	N/A	-192.88%
Return on Assets (ROA)	-9.92%	-45.96%	-31.33%	N/A	-97.89%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	2.79%	0.05%	N/A	N/A
Current Ratio	6.91%	1.80%	5.65%	N/A	5.65%
Quick Ratio	6.91%	1.64%	5.65%	N/A	5.65%
Ownership Information
Institutional Ownership Percentage	57.48%	20.36%	33.39%	10.60%	9.91%
Insider Ownership Percentage	15.40%	N/A	4.02%	N/A	3.60%
Miscellaneous
Employees	83	182	56	141	18
Shares Outstanding	34.22 million	46.40 million	26.00 million	34.95 million	195.69 million
Next Earnings Date	8/11/2021 (Estimated)	5/26/2021 (Estimated)	8/12/2021 (Estimated)	N/A	7/30/2021 (Estimated)
Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018) finance.yahoo.com - May 10 at 10:15 AM
	EXCLUSIVE: Ampio Pharmaceuticals Approved For Clinical Study Of Lead Drug In Long-Term Respiratory COVID-19 Symptoms feeds.benzinga.com - May 10 at 9:18 AM
	Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Releases Earnings Results, Hits Estimates americanbankingnews.com - May 6 at 2:52 PM
	Ampio: Q1 Earnings Snapshot abqjournal.com - May 5 at 6:16 PM
	Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update finance.yahoo.com - May 5 at 4:07 PM
	Why should you add Ampio Pharmaceuticals Inc. (AMPE) to your portfolio? marketingsentinel.com - May 5 at 11:07 AM
	Insider Selling: Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Director Sells 20,000 Shares of Stock americanbankingnews.com - April 30 at 6:10 PM
	Holli Cherevka Sells 74,631 Shares of Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Stock americanbankingnews.com - April 30 at 4:52 PM
	Ampio Pharmaceuticals, Inc. (NYSE:AMPE) Stock Jumped 17.39% Over A Month – Is There Any Hope Of Further Gain? marketingsentinel.com - April 30 at 12:49 PM
	Ampio Pharmaceuticals, Inc. (NYSE:AMPE)’s Upside Potential Is High stocksregister.com - April 29 at 1:24 PM
	Ampio Pharmaceuticals Inc. [AMPE] moved up 3.21: Why It’s Important dbtnews.com - April 29 at 12:04 AM
	Ampio Pharmaceuticals (AMPE) Scheduled to Post Earnings on Wednesday americanbankingnews.com - April 28 at 6:30 AM
	Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality finance.yahoo.com - April 27 at 1:55 PM
	Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19 finance.yahoo.com - April 27 at 9:24 AM
	Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80% finance.yahoo.com - April 27 at 9:24 AM
	Ampio Pharmaceuticals, Inc. (NYSE:AMPE)up 3.21%: This is what analysts are now forecasting stocksregister.com - April 22 at 9:07 AM
	Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update finance.yahoo.com - April 21 at 10:22 AM
	Ampio Pharmaceuticals, Inc. (NYSE:AMPE) Stock Could Reward Investors With a 154.78% Gain marketingsentinel.com - April 20 at 12:34 PM
	Ampio Pharmaceuticals, Inc. (NYSE:AMPE) Stock Forecast: Bullish Sentiment Portends 154.78% Upside in 2021 stocksregister.com - April 19 at 10:18 AM
	Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects finance.yahoo.com - April 19 at 10:02 AM
	Is Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a Good Pick for New Investors Now? stocksregister.com - April 12 at 6:59 PM
	Ampio posts encouraging results from Ampion COVID-19 pre-clinical study seekingalpha.com - April 8 at 1:57 PM
	Ampio Pharmaceuticals' Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis finance.yahoo.com - April 6 at 10:11 AM
	Ampio Pharmaceuticals is Building on its Progress in Tackling Osteoarthritis and COVID-19 Respiratory Issues markets.businessinsider.com - April 1 at 12:29 PM
	Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress finance.yahoo.com - March 29 at 9:32 AM

Date	Company	Brokerage	Action
3/30/2021	Frequency Therapeutics	Oppenheimer	Lower Price Target
3/24/2021	Frequency Therapeutics	B. Riley	Lower Price Target
1/27/2021	Frequency Therapeutics	JPMorgan Chase & Co.	Upgrade
11/18/2019	Frequency Therapeutics	Cowen	Reiterated Rating
10/28/2019	Frequency Therapeutics	The Goldman Sachs Group	Initiated Coverage
11/12/2020	RedHill Biopharma	Roth Capital	Lower Price Target
10/13/2020	RedHill Biopharma	Ascendiant Capital Markets	Reiterated Rating
9/11/2020	RedHill Biopharma	BTIG Research	Initiated Coverage
3/5/2020	RedHill Biopharma	HC Wainwright	Reiterated Rating
7/12/2019	RedHill Biopharma	WBB Securities	Upgrade
12/12/2018	RedHill Biopharma	LADENBURG THALM/SH SH	Set Price Target
4/14/2021	Hookipa Pharma	Morgan Stanley	Initiated Coverage
3/21/2021	Hookipa Pharma	SVB Leerink	Reiterated Rating
11/30/2020	Hookipa Pharma	JMP Securities	Boost Price Target
11/3/2020	Hookipa Pharma	Truist Financial	Initiated Coverage
8/16/2020	Hookipa Pharma	Royal Bank of Canada	Reiterated Rating
5/13/2019	Hookipa Pharma	Bank of America	Initiated Coverage
10/26/2020	Orphazyme A/S	Guggenheim	Initiated Coverage

(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources